Magic mushroom compound may rewire the brain for happiness

NCT ID NCT06692192

Recruiting now Knowledge-focused Sponsor: University of Wisconsin, Madison Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This study tests whether psilocybin, the active ingredient in magic mushrooms, can improve emotional wellbeing by promoting brain plasticity. Sixty adults with mild emotional decline will receive different doses of psilocybin, sometimes combined with a drug that causes temporary amnesia. Researchers will use brain scans and questionnaires to measure changes in mood and brain function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Psilocybin
What this could lead to: If successful, this could help explain how psilocybin improves wellbeing by changing the brain, pointing toward new ways to treat emotional distress.
What could go wrong: This is an early Phase 1 study with only 60 people, so results may not apply broadly. The low dose and amnesia-inducing drug may limit effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSILOCYBIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PSILOCYBIN

Contacts and locations

Locations

UW School of Medicine and Public Health
RECRUITING

Madison, Wisconsin, 53792, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.